STOCK TITAN

Sangamo Therapeutics: Armistice reports 9.79% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Sangamo Therapeutics, Inc. (SGMOQ) ownership amendment reports that Armistice Capital, LLC and Steven Boyd each report beneficial ownership of 40,560,819 shares, or 9.79% of the class, for the September 30, 2026 event date. Both report shared voting and dispositive power over the same shares.

The Master Fund is the direct holder and has the right to receive dividends or sale proceeds. Armistice Capital exercises voting and investment power under an Investment Management Agreement; Boyd, its managing member, may be deemed to beneficially own the securities.

Beneficial ownership 40,560,819 shares Reported by each reporting person for the September 30, 2026 event date; the same shares are reported by both.
Percent of class 9.79% Reported beneficial ownership percentage for each reporting person.
beneficial ownership regulatory
"disclaims beneficial ownership of the securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting power regulatory
"Shared Voting Power 40,560,819.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared Dispositive Power 40,560,819.00"
Investment Management Agreement technical
"pursuant to an Investment Management Agreement"
An investment management agreement is a written contract that hires a professional to make buying, selling and strategy decisions for an investment account or fund, and sets out their duties, fees, risk limits, performance measures and reporting requirements. It matters to investors because the agreement determines who controls the money, how much the service costs, what risks are allowed, and how success or failure is measured—think of it as the service contract that defines expectations and remedies for a hired portfolio manager.
Rule 13d-1(k) regulatory
"JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Sangamo Therapeutics (SGMOQ) shares did Armistice Capital report owning?

Armistice Capital reported beneficial ownership of 40,560,819 shares, or 9.79% of the class. Steven Boyd reported the same amount; both reports describe shared voting and dispositive power over the shares.

Who directly holds the shares reported for Sangamo Therapeutics (SGMOQ)?

The Armistice Capital Master Fund is the direct holder and has the right to receive dividends or proceeds from a sale. Armistice Capital exercises voting and investment power under an Investment Management Agreement, and Steven Boyd, its managing member, may be deemed to beneficially own the securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





800677106

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:11/16/2026
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:11/16/2026
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: November 16, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

Keep reading